Research

UTHealth a Site for First-Ever Large NIDA Trial For Methamphetamine Use Disorder


Schmitz
By Deborah Mann Lake | June 13, 2017

With the rates of methamphetamine use reaching an all-time high in Texas, raising alarms for the Greater Houston area, McGovern Medical School at The University of Texas Health Science Center at Houston (UTHealth) researchers have launched a clinical trial to study a combination of medications designed to treat methamphetamine use disorder.

The Center for Neurobehavioral Research on Addiction (CNRA) in the Department of Psychiatry and Behavioral Sciences at UTHealth is one of just seven sites for the study as part of the National Institute on Drug Abuse Clinical Trials Network (NIDA CTN). The clinical trial brings a $930,000 grant to the CNRA, which is the only enrolling site in Texas.

Due to a more potent form of the drug coming out of Mexico, methamphetamine use in Texas is now higher than even the highest levels documented before the 2006 ban on the sale of pseudoephedrine, according to the August 2016 report of the NIDA-funded National Drug Early Warning System (NDEWS). The Drug Enforcement Administration (DEA) ranked methamphetamine as the No. 1 drug threat in the Dallas DEA area and No. 2 in the Houston DEA area. The NDEWS report also revealed that poison control calls about methamphetamine exposure are at the highest level ever in the state and admissions to treatment programs have increased from 3 percent of all admissions in 1999 to 16 percent in 2015.

“Methamphetamine is one of the most highly addictive and destructive drugs on the illicit market. Unfortunately, effective treatment options for methamphetamine dependence are extremely limited,” said Joy Schmitz, Ph.D., director of the CNRA and the Louis A. Faillace, M.D., Professor at McGovern Medical School at UTHealth. “The CNRA is excited to be part of the first-ever large, multisite national study that could have a huge impact on improving treatment of methamphetamine addiction by studying a promising new medication combination.”

The clinical trial will examine whether a combination of naltrexone and bupropion works better than placebo to help methamphetamine addiction. Both medications are approved by the Federal Drug Administration for other disorders.

Methamphetamine is a stimulant that increases levels of dopamine in the brain. Unlike cocaine, which has a similar effect, methamphetamine stays in the brain longer, leading to prolonged stimulant effects before the inevitable crash. Increasing use can lead to cardiovascular problems such as high blood pressure and an irregular heartbeat, as well as hyperthermia, structural damage to the brain, convulsions and death. Chronic users can develop anxiety, confusion, mood disturbances and violent behavior.

“A person who uses it regularly can have a psychotic break and begin feeling, hearing or seeing things,” said co-investigator Michael Weaver, M.D., professor and medical director of the CNRA. “They can develop tactile hallucinations and feel like bugs are crawling on them, scratching to the point where they develop large sores.”

Psychotic symptoms can sometimes last for months or years after a person has quit abusing methamphetamine, according to the NIDA.

The UTHealth site will enroll 55 participants of the 370 recruited nationally. Eligible participants (18 to 65 years old) will have clinic visits twice a week, receive 12 weeks of medication, and be compensated for study activities. Participation is voluntary and possible risks and benefits will be discussed. For more information about the study, call 713-486-2635 or email ms.CNRAresearch@.uth.tmc.edu.

Other UTHealth faculty involved in this study include Angela Stotts, Ph.D.; Thomas Northrup, Ph.D.; Yolanda Villarreal, Ph.D.; and Raymond Cho, M.D., M.Sc. Team members include research coordinator Jessica Vincent, research assistant Tasha Davis, recruiter specialist Rolanda Johnson, M.S., and research nurse Ife Ifelayo, R.N.

Tags | Research



Social Posts

profile_image

BCMHouston

@bcmhouston

Don't forget to join us next Saturday for Rare Disease Day Houston! https://t.co/Ga2bNYWDmk #RareDiseaseDay… https://t.co/j7FxftkEGD

57 mins ago
profile_image

Veterans Affairs

@DeptVetAffairs

Marine Veteran @JohnPrestonUSA shares his experience pursuing a career in the music industry https://t.co/4aXpqyZTQW #VApodcast

57 mins ago
profile_image

Veterans Affairs

@DeptVetAffairs

10 Veterans and their wives renew marriage vows on Valentine's Day at Cleveland VA https://t.co/kc97p3AvAC via @HomaBashWEWS

2 hours ago
profile_image

MD Anderson Cancer Center

MDAnderson

Whether you’re traveling one mile or 1,000 miles to get to MD Anderson, packing for your first visit can seem overwhelming. Try these tips from veteran cancer...

2 hours ago
profile_image

Rice University

@RiceUniversity

Mark your calendars! Next Friday (Feb. 23) the @MoodyArts will celebrate its 1st birthday with a bang 🎆 Details—… https://t.co/gHpfsaJ190

2 hours ago
profile_image

MD Anderson Cancer Center

@MDAndersonNews

Hear our @aiims1742 discuss how our Pancreatic #CancerMoonshot aims to improve #pancreaticcancer diagnosis and trea… https://t.co/MYfErUasO9

3 hours ago
profile_image

Veterans Affairs

@DeptVetAffairs

Meet #Olympics2018 athlete @USArmy @usarmywcap Sgt. Nick Cunningham https://t.co/NeI0Ta1Agm #TeamUSA https://t.co/VZ0GufuYol

3 hours ago
profile_image

BCMHouston

@bcmhouston

Dr. Asim Shah gives tips on what you should do if you see a change in a friend's behavior on social media. https://t.co/xrXc7EtATO

5 hours ago
profile_image

Baylor College of Medicine

BaylorCollegeOfMedicine

What do you know about your lipoprotein(a) level? Our experts find this protein could be the strongest inherited risk factor for heart attacks and strokes. http...

5 hours ago
profile_image

U.S. Department of Veterans Affairs

VeteransAffairs

With bobsled events getting underway this weekend at the Winter Olympics, meet some of the Army athletes who will be competing.

6 hours ago
profile_image

Rice University

@RiceUniversity

https://t.co/GnWXDBRM3I

6 hours ago
profile_image

CHI St. Luke's Health

CHIStLukes

Baylor St. Luke’s Medical Center is the first hospital in Texas to offer PulseRider technology for the minimally invasive treatment of complex brain aneurysms, ...

6 hours ago
profile_image

CHI St. Luke's Health

CHIStLukes

We are honored that Baylor St. Luke’s Medical Center neurosurgeon, Dr. Sameer Sheth, was awarded an $8.5 million grant by the BRAIN Initiative to pioneer the st...

6 hours ago
profile_image

CHI St Luke's Health

@CHI_StLukes

We are honored that Baylor St. Luke’s neurosurgeon, Dr. Sameer Sheth, was awarded an $8.5 million grant by the BRAI… https://t.co/RlQKGPC2Kp

6 hours ago
profile_image

MD Anderson Cancer Center

@MDAndersonNews

We’re proud to have these talented scientists helping us #endcancer. https://t.co/tHFWDAjn3k

7 hours ago